Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Cancer Biomarkers : Section a of Disease Markers|November 3, 2011
FDG-PET/CT as a molecular biomarker in ovarian cancerEwa Nowosinska, Stefanie Avril, Iain Murray, et al.
Gynecologic Oncology|January 9, 2007
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancerMelissa M Thrall, Julie A DeLoia, Holly Gallion, et al.
European Urology|February 6, 2007
Molecular positron emission tomography and PET/CT imaging in urological malignanciesTom Powles, Iain Murray, Cathryn Brock, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 7, 2012
The role of FDG-PET/CT in gynaecological cancersAndrea G Rockall, Susan Cross, Sean Flanagan, et al.
Clinical Nuclear Medicine|July 19, 2005
FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapyJudith M Joyce, Berna Degirmenci, Samuel Jacobs, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
Utility of PET in Breast CancerNorbert Avril, Marcus Schelling, Jorg Dose, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 8, 2010
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancersNorbert Avril, Fatima Dambha, Iain Murray, et al.
Nuclear Medicine Communications|July 8, 2005
Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patientsLuis Gorospe, Subha Raman, Jon Echeveste, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2005
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PETJoerg Dose Schwarz, Michael Bader, Lars Jenicke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapySamuel A Jacobs, Nicholas Vidnovic, Judith Joyce, et al.
Pageof 9